Tempero Bio is a clinical-stage biopharmaceutical company advancing TMP-301, a next-generation mGluR5 negative allosteric modulator (NAM) designed to prevent relapse by targeting the biology of addiction. TMP-301 has shown promising results in preclinical models of alcohol, cocaine and opiate use disorders and has been evaluated in over 80 healthy volunteers in Phase 1 with an acceptable safety and tolerability profile and robust PET-measured receptor occupancy. The company has initiated a Phase 2 trial in alcohol use disorder and a drug–drug interaction study in people using cocaine, with a Phase 2 cocaine trial planned following the DDI study. Tempero plans to use new financing to support two Phase 2 clinical trials, Phase 3-enabling activities, and additional preclinical studies and formulation work. The company is focused on addressing large unmet needs—there are no FDA-approved medications for cocaine use disorder and high prevalence of alcohol and drug use disorders drives demand for new therapies. Tempero Bio is an Aditum Bio portfolio company and recently announced John Wagner, M.D., Ph.D., will join as Chief Medical Officer.

Total raised

$70M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2025